BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20409340)

  • 1. Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits.
    Radaelli A; Pozzi E; Pacchioni S; Zanotto C; Morghen Cde G
    J Transl Med; 2010 Apr; 8():40. PubMed ID: 20409340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.
    Bissa M; Illiano E; Pacchioni S; Paolini F; Zanotto C; De Giuli Morghen C; Massa S; Franconi R; Radaelli A; Venuti A
    J Transl Med; 2015 Mar; 13():80. PubMed ID: 25763880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers.
    Radaelli A; De Giuli Morghen C; Zanotto C; Pacchioni S; Bissa M; Franconi R; Massa S; Paolini F; Muller A; Venuti A
    Virus Res; 2012 Dec; 170(1-2):44-52. PubMed ID: 22951311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins.
    Pozzi E; Basavecchia V; Zanotto C; Pacchioni S; Morghen Cde G; Radaelli A
    J Virol Methods; 2009 Jun; 158(1-2):184-9. PubMed ID: 19428588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.
    Illiano E; Bissa M; Paolini F; Zanotto C; De Giuli Morghen C; Franconi R; Radaelli A; Venuti A
    Virus Res; 2016 Oct; 225():82-90. PubMed ID: 27664839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects.
    Peng S; Tomson TT; Trimble C; He L; Hung CF; Wu TC
    Gene Ther; 2006 Feb; 13(3):257-65. PubMed ID: 16177818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.
    Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T
    J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells.
    Wu XM; Liu X; Jiao QF; Fu SY; Bu YQ; Song FZ; Yi FP
    Asian Pac J Cancer Prev; 2014; 15(6):2447-51. PubMed ID: 24761845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
    Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
    Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy.
    Thornburg C; Boczkowski D; Gilboa E; Nair SK
    J Immunother; 2000; 23(4):412-8. PubMed ID: 10916750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
    Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
    Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
    Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
    J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
    Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
    Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.
    Hu D; Zhou J; Wang F; Shi H; Li Y; Li B
    Arch Gynecol Obstet; 2015 Dec; 292(6):1345-54. PubMed ID: 26093522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR9 expression in uterine cervical lesions of Uyghur women correlate with cervical cancer progression and selective silencing of human papillomavirus 16 E6 and E7 oncoproteins in vitro.
    Hao Y; Yuan JL; Abudula A; Hasimu A; Kadeer N; Guo X
    Asian Pac J Cancer Prev; 2014; 15(14):5867-72. PubMed ID: 25081715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract.
    Henkle TR; Lam B; Kung YJ; Lin J; Tseng SH; Ferrall L; Xing D; Hung CF; Wu TC
    Cancer Res; 2021 Sep; 81(17):4560-4569. PubMed ID: 34215618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
    Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
    Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.